Using technology originally adapted for HER2/neu assessment in breast cancer,16 we developed a new clinical grade, automated chromogenic assay to assess MYC and PTEN status simultaneously on a single biopsy slide. This evidence concerns the gene ERBB2 and breast carcinoma.